Opigolix
| Opigolix | |
|---|---|
| Opigolix.svg | |
| INN | |
| Drug class | |
| Routes of administration | |
| Pregnancy category | |
| Bioavailability | |
| Metabolism | |
| Elimination half-life | |
| Excretion | |
| Legal status | |
| CAS Number | |
| PubChem | |
| DrugBank | |
| ChemSpider | |
| KEGG | |
Opigolix is a medication that acts as a selective antagonist of the gonadotropin-releasing hormone receptor (GnRH receptor). It is primarily used in the treatment of hormone-dependent conditions such as endometriosis and uterine fibroids.
Mechanism of Action[edit]
Opigolix functions by inhibiting the action of gonadotropin-releasing hormone (GnRH), a key hormone in the regulation of the reproductive system. By blocking the GnRH receptor, Opigolix reduces the secretion of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) from the pituitary gland. This leads to a decrease in the production of estrogen and progesterone by the ovaries, which are hormones involved in the pathophysiology of conditions like endometriosis.
Pharmacokinetics[edit]
Opigolix is administered orally and is absorbed through the gastrointestinal tract. It undergoes hepatic metabolism and is primarily excreted via the kidneys. The drug has a half-life that allows for once or twice daily dosing, depending on the therapeutic regimen.
Clinical Uses[edit]
Opigolix is used in the management of:
- Endometriosis: A condition characterized by the presence of endometrial tissue outside the uterus, leading to pain and infertility.
- Uterine fibroids: Non-cancerous growths in the uterus that can cause heavy menstrual bleeding and pelvic pain.
Side Effects[edit]
Common side effects of Opigolix include:
- Hot flashes
- Headaches
- Nausea
- Decreased bone mineral density with long-term use
Contraindications[edit]
Opigolix is contraindicated in patients with:
- Known hypersensitivity to the drug
- Pregnancy, due to potential harm to the fetus
- Severe liver impairment
Related pages[edit]
-
Opigolix
